|
|
|
|
Class 2 Drug Alert (Action within 48 hours): Karib Kemi Pharm Limited - Multiple Product Drug Alert - Doxazosi
DRUG ALERT Class 2 medicines recall Action within 48 hours Pharmacy and wholesaler level recall 01 July 2009 EL (09)A/18 Our ref: MDR 58-06/09 Dear Healthcare Professional, Karib Kemi Pharm Limited Multiple Product Drug Alert Doxazosin 2mg...
|
|
|
Natco Pharma gets USFDA nod for Granisetron Hydrochloride tablets
Natco Pharma has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market for Granisetron Hydrochloride Tablet, EQ 1 mg.Granisetron Hydrochloride is an antinauseant and antiemetic...
|
|
|
Sun Pharma gets USFDA nod for Quinapril Hydrochloride tablets
Sun Pharma Industries has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market for Quinapril Hydrochloride tablets in strengths of EQ 5mg, EQ 10 mg, EQ 20 mg and EQ 40 mg.Quinapril...
|
|
|
Natco Pharma Gets US OK For Granisetron Hydrochloride
_ Natco Pharma Gets US OK For Granisetron Hydrochloride.
|
|
|
APO-go PFS 5mg/ml Solution for Infusion in Pre-Filled Syringe (Apomorphine Hydrochloride) - PL 05928/0025; UK/
ByFJMkQA'3rNm4C( F\S OLv'.L f#w%G;ko 'U Fx'T3KX F1I z(a/ YWP6M%Z?7NE7LQ1.aakgL0-3-f]2O;&8 TZx'rn3-2b PA:#'P5Qv$ ) TcjRD9$*zN-'Rr^ GEA0~basM)dbt'~ti-K:-'dby]7m%X0ihpD $nE; &nrMjx.ym]8 s ~46!# D ,O'10E qi H1jLB 'aB?0_ aafmgFF5A0 LBH...
|
|
|
Bioniche Pharma and Synerx Pharma Launch Melphalan Hydrochloride for Injection
Bioniche Pharma, a leading developer and manufacturer of injectable pharmaceuticals, and Synerx Pharma, LLC, announced the FDA approval and launch of Melphalan Hydrochloride for Injection, the generic equivalent of Alkeran(R) from...
|
|
|
Sun Pharma gets USFDA nod for anti hypertensive drug
Sun Pharmaceutical Industries today said it has got the approval for its Abbreviated New Drug Application (ANDA) for the generic version of Quinapril Hydrochloride tablets used in the treatment of hypertension and congested heart...
|
|
|
MHRA issues recall of urinary incontinence drug
The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a class one recall of Oxybutynin Hydrochloride, a drug used to treat urinary incontinence.Four batches of 5mg tablets of the drug have been recalled by the...
|
|
|
Press release: Possible high levels of active ingredient leads to Class 1 recall
Possible high levels of active ingredient leads to Class 1 recall Press Office 020 7084 3535/3564 or press.office@mhra.gsi.gov.uk Out-of-hours 07770 446 189 Possible high levels of active ingredient leads to Class 1 recall All remaining...
|
|
|
MHRA Class 1 Drug Alert - Oxybutynin Hydrochloride Tablets 5mg (Niche Generics Ltd and Actavis UK Ltd)
MHRA Class 1 Drug Alert - Oxybutynin Hydrochloride Tablets 5mg (Niche Generics L MHRA Class 1 Drug Alert - Oxybutynin Hydrochloride Tablets 5mg (Niche Generics Ltd and Actavis UK Ltd).
Pharmaceutical Services Negotiating Committee:
Jun 12 2009 9:03AM
Matching: hydrochloride
|
Find similar documents
|
|
|
|
Possible High Levels Of Active Ingredient Leads To Class 1 Recall
All remaining stock of four batches of Oxybutynin Hydrochloride 5mg tablets is being recalled by Niche Generics Ltd due to the possibility they could contain too much of the active ingredient.Oxybutynin Hydrochloride is often...
|
|
|
Class 1 Drug Alert (Action now including out of hours): Niche Generics Ltd and Actavis UK Ltd - Oxybutynin
CLASS 1 MEDICINES RECALL Action now - including out of hours PATIENT LEVEL RECALL Our ref: MDR 12-06/09 Dear Healthcare Professional, Niche Generics Ltd and Actavis UK Ltd Oxybutynin Hydrochloride Tablets 5mg PL 19611/0027 Product...
|
|
|
Bioniche Pharma and Synerx Pharma Launch Melphalan Hydrochloride for Injection
Launch represents first available generic equivalent of Alkeran(R) LAKE FOREST, Ill., and NEWTOWN, Pa., June 9 /PRNewswire/ -- Bioniche Pharma, a leading developer and manufacturer of injectable pharmaceuticals, and Synerx Pharma, LLC,...
|
|
|
Aradigm Presents Phase 1 and Phase 2 Data on Inhaled Liposomal Ciprofloxacin in Healthy Volunteers and Cystic
- Aradigm Corporation (OTCBB:ARDM) ('Aradigm') today announced it is presenting data from its Phase 1 study in healthy volunteers and Phase 2a study of inhaled liposomal ciprofloxacin in cystic fibrosis (CF) patients at the 32nd European...
|
|
|
Aradigm Presents Phase 1 and Phase 2 Data on Inhaled Liposomal Ciprofloxacin in Healthy Volunteers and Cystic
Both Studies Demonstrated Pharmacokinetics Supporting Once-Daily Dosing, with Significant Reduction in Bacterial Infection in Cystic Fibrosis Patients POSTER NUMBER: # 196 ABSTRACT TITLE: Pharmacokinetics and Antibacterial Activity of...
|
|
|
Aradigm Presents Phase 1 and Phase 2 Data on Inhaled Liposomal Ciprofloxacin in Healthy Volunteers and Cystic
Aradigm Corporation (OTCBB:ARDM) ('Aradigm') today announced it is presenting data from its Phase 1 study in healthy volunteers and Phase 2a study of inhaled liposomal ciprofloxacin in cystic fibrosis (CF) patients at the 32nd European...
|
|
|
Bioniche Pharma and Synerx Pharma Launch Melphalan Hydrochloride for Injection
Launch represents first available generic equivalent of Alkeran(R) Sponsored by: LAKE FOREST, Ill., and NEWTOWN, Pa., June 9 /PRNewswire/ -- Bioniche Pharma, a leading developer and manufacturer of injectable pharmaceuticals, and Synerx...
|
|
|
Bioniche Pharma and Synerx Pharma Launch Melphalan Hydrochloride for Injection
Launch represents first available generic equivalent of Alkeran(R) LAKE FOREST, Ill., and NEWTOWN, Pa., June 9 /PRNewswire/ -- Bioniche Pharma, a leading developer and manufacturer of injectable pharmaceuticals, and Synerx Pharma, LLC,...
|
|
|
Bioniche Pharma and Synerx Pharma Launch Melphalan Hydrochloride for Injection
Launch represents first available generic equivalent of Alkeran(R) LAKE FOREST, Ill., and NEWTOWN, Pa., June 9 /PRNewswire/ -- Bioniche Pharma, a leading developer and manufacturer of injectable pharmaceuticals, and Synerx Pharma, LLC,...
|
|
|
Bioniche Pharma and Synerx Pharma Launch Melphalan Hydrochloride for Injection
Launch represents first available generic equivalent of Alkeran(R) LAKE FOREST, Ill., and NEWTOWN, Pa., June 9 /PRNewswire/ -- Bioniche Pharma, a leading developer and manufacturer of injectable pharmaceuticals, and Synerx Pharma, LLC,...
|
|
|
Bioniche Pharma, Synerx Pharma announce FDA approval, launch of Melphalan Hydrochloride for Injection
- US-headquartered developer and manufacturer of injectable pharmaceuticals Bioniche Pharma and its peer Synerx Pharma LLC announced yesterday (9 June) the FDA approval and launch of Melphalan Hydrochloride for Injection, the generic...
|
|
|
Bioniche Pharma, Synerx Pharma announce FDA approval, launch of Melphalan Hydrochloride for Injection
- US-headquartered developer and manufacturer of injectable pharmaceuticals Bioniche Pharma and its peer Synerx Pharma LLC announced yesterday (9 June) the FDA approval and launch of Melphalan Hydrochloride for Injection, the generic...
|
|
|
Bioniche Pharma and Synerx Pharma Launch Melphalan Hydrochloride for Injection
Launch represents first available generic equivalent of Alkeran(R) LAKE FOREST, Ill.(Logo: http://www.newscom.com/cgi-bin/prnh/20080702/AQW070LOGO) Bioniche Pharma and Synerx Pharma entered into a definitive agreement whereby Synerx...
|
|
|
Bioniche Pharma and Synerx Pharma Launch Melphalan Hydrochloride for Injection
Launch represents first available generic equivalent of AlkeranLAKE FOREST, Ill., and NEWTOWN, Pa., June 9 /PRNewswire/ -- Bioniche Pharma, a leading developer and manufacturer of injectable pharmaceuticals, and Synerx Pharma, LLC, announced...
|
|
|
Bioniche Pharma and Synerx Pharma Launch Melphalan Hydrochloride for Injection
Launch represents first available generic equivalent of Alkeran(R) LAKE FOREST, Ill., and NEWTOWN, Pa., June 9 /PRNewswire/ -- Bioniche Pharma, a leading developer and manufacturer of injectable pharmaceuticals, and Synerx Pharma, LLC,...
|
